Vascular  ||| S:0 E:9 ||| NNP
Accessibility  ||| S:9 E:23 ||| NNP
of  ||| S:23 E:26 ||| IN
Endothelial  ||| S:26 E:38 ||| NNP
Targeted  ||| S:38 E:47 ||| NNP
Ferritin  ||| S:47 E:56 ||| NNP
Nanoparticles  ||| S:56 E:70 ||| NNP
Targeting  ||| S:70 E:80 ||| NNP
nanocarriers  ||| S:80 E:93 ||| VBD
to  ||| S:93 E:96 ||| TO
the  ||| S:96 E:100 ||| DT
endothelium ||| S:100 E:111 ||| NN
,  ||| S:111 E:113 ||| ,
using  ||| S:113 E:119 ||| VBG
affinity  ||| S:119 E:128 ||| JJ
ligands  ||| S:128 E:136 ||| NN
to  ||| S:136 E:139 ||| TO
cell  ||| S:139 E:144 ||| VB
adhesion  ||| S:144 E:153 ||| JJ
molecules  ||| S:153 E:163 ||| NNS
such  ||| S:163 E:168 ||| JJ
as  ||| S:168 E:171 ||| IN
ICAM-1  ||| S:171 E:178 ||| NNP
and  ||| S:178 E:182 ||| CC
PECAM-1 ||| S:182 E:189 ||| NNP
,  ||| S:189 E:191 ||| ,
holds  ||| S:191 E:197 ||| VBZ
promise  ||| S:197 E:205 ||| NN
to  ||| S:205 E:208 ||| TO
improve  ||| S:208 E:216 ||| VB
the  ||| S:216 E:220 ||| DT
pharmacotherapy  ||| S:220 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
many  ||| S:239 E:244 ||| JJ
disease  ||| S:244 E:252 ||| NN
conditions ||| S:252 E:262 ||| NNS
.  ||| S:262 E:264 ||| .
This  ||| S:264 E:269 ||| DT
approach  ||| S:269 E:278 ||| NN
capitalizes  ||| S:278 E:290 ||| NN
on  ||| S:290 E:293 ||| IN
the  ||| S:293 E:297 ||| DT
observation  ||| S:297 E:309 ||| NN
that  ||| S:309 E:314 ||| IN
antibody-targeted  ||| S:314 E:332 ||| JJ
carriers  ||| S:332 E:341 ||| NNS
of  ||| S:341 E:344 ||| IN
100  ||| S:344 E:348 ||| CD
nm  ||| S:348 E:351 ||| NNS
and  ||| S:351 E:355 ||| CC
above  ||| S:355 E:361 ||| IN
accumulate  ||| S:361 E:372 ||| NN
in  ||| S:372 E:375 ||| IN
the  ||| S:375 E:379 ||| DT
pulmonary  ||| S:379 E:389 ||| JJ
vasculature  ||| S:389 E:401 ||| NN
more  ||| S:401 E:406 ||| RBR
effectively  ||| S:406 E:418 ||| RB
than  ||| S:418 E:423 ||| IN
free  ||| S:423 E:428 ||| JJ
antibodies ||| S:428 E:438 ||| NNS
.  ||| S:438 E:440 ||| .
Targeting  ||| S:440 E:450 ||| VBG
of  ||| S:450 E:453 ||| IN
prospective  ||| S:453 E:465 ||| JJ
nanocarriers  ||| S:465 E:478 ||| NN
in  ||| S:478 E:481 ||| IN
the  ||| S:481 E:485 ||| DT
10-50  ||| S:485 E:491 ||| JJ
nm  ||| S:491 E:494 ||| JJ
range ||| S:494 E:499 ||| NN
,  ||| S:499 E:501 ||| ,
however ||| S:501 E:508 ||| RB
,  ||| S:508 E:510 ||| ,
has  ||| S:510 E:514 ||| VBZ
not  ||| S:514 E:518 ||| RB
been  ||| S:518 E:523 ||| VBN
studied ||| S:523 E:530 ||| VBN
.  ||| S:530 E:532 ||| .
To  ||| S:532 E:535 ||| TO
address  ||| S:535 E:543 ||| VB
this  ||| S:543 E:548 ||| DT
intriguing  ||| S:548 E:559 ||| JJ
issue ||| S:559 E:564 ||| NN
,  ||| S:564 E:566 ||| ,
we  ||| S:566 E:569 ||| PRP
conjugated  ||| S:569 E:580 ||| VBP
monoclonal  ||| S:580 E:591 ||| JJ
antibodies  ||| S:591 E:602 ||| NNS
( ||| S:602 E:603 ||| -LRB-
Ab ||| S:603 E:605 ||| NNP
)  ||| S:605 E:607 ||| -RRB-
to  ||| S:607 E:610 ||| TO
ICAM-1  ||| S:610 E:617 ||| CD
and  ||| S:617 E:621 ||| CC
PECAM-1  ||| S:621 E:629 ||| NNP
or  ||| S:629 E:632 ||| CC
their  ||| S:632 E:638 ||| PRP$
single  ||| S:638 E:645 ||| JJ
chain  ||| S:645 E:651 ||| NN
antigen-binding  ||| S:651 E:667 ||| JJ
fragments  ||| S:667 E:677 ||| NNS
( ||| S:677 E:678 ||| -LRB-
scFv ||| S:678 E:682 ||| NNP
)  ||| S:682 E:684 ||| -RRB-
to  ||| S:684 E:687 ||| TO
ferritin  ||| S:687 E:696 ||| VB
nanoparticles  ||| S:696 E:710 ||| NNS
( ||| S:710 E:711 ||| -LRB-
FNPs ||| S:711 E:715 ||| NNP
,  ||| S:715 E:717 ||| ,
size  ||| S:717 E:722 ||| NN
12  ||| S:722 E:725 ||| CD
nm ||| S:725 E:727 ||| CD
) ||| S:727 E:728 ||| -RRB-
,  ||| S:728 E:730 ||| ,
thereby  ||| S:730 E:738 ||| RB
producing  ||| S:738 E:748 ||| VBG
Ab ||| S:748 E:750 ||| NNP
/ ||| S:750 E:751 ||| NNP
FNPs  ||| S:751 E:756 ||| NNP
and  ||| S:756 E:760 ||| CC
scFv ||| S:760 E:764 ||| NNP
/ ||| S:764 E:765 ||| NNP
FNPs ||| S:765 E:769 ||| NNP
.  ||| S:769 E:771 ||| .
Targeted  ||| S:771 E:780 ||| NNP
FNPs  ||| S:780 E:785 ||| NNP
retained  ||| S:785 E:794 ||| VBD
their  ||| S:794 E:800 ||| PRP$
typical  ||| S:800 E:808 ||| JJ
symmetric  ||| S:808 E:818 ||| JJ
core-shell  ||| S:818 E:829 ||| JJ
structure  ||| S:829 E:839 ||| NN
with  ||| S:839 E:844 ||| IN
sizes  ||| S:844 E:850 ||| NNS
of  ||| S:850 E:853 ||| IN
20-25  ||| S:853 E:859 ||| CD
nm  ||| S:859 E:862 ||| NNS
and  ||| S:862 E:866 ||| CC
∼4-5  ||| S:866 E:871 ||| NNP
Ab  ||| S:871 E:874 ||| NNP
( ||| S:874 E:875 ||| -LRB-
or  ||| S:875 E:878 ||| CC
∼7-9  ||| S:878 E:883 ||| NNP
scFv ||| S:883 E:887 ||| NNP
)  ||| S:887 E:889 ||| -RRB-
per  ||| S:889 E:893 ||| FW
particle ||| S:893 E:901 ||| FW
.  ||| S:901 E:903 ||| .
Ab ||| S:903 E:905 ||| NNP
/ ||| S:905 E:906 ||| NNP
FNPs  ||| S:906 E:911 ||| NNP
and  ||| S:911 E:915 ||| CC
scFv ||| S:915 E:919 ||| NNP
/ ||| S:919 E:920 ||| NNP
FNPs ||| S:920 E:924 ||| NNP
,  ||| S:924 E:926 ||| ,
but  ||| S:926 E:930 ||| CC
not  ||| S:930 E:934 ||| RB
control  ||| S:934 E:942 ||| VB
IgG ||| S:942 E:945 ||| JJ
/ ||| S:945 E:946 ||| NNP
FNPs ||| S:946 E:950 ||| NNP
,  ||| S:950 E:952 ||| ,
bound  ||| S:952 E:958 ||| VBN
specifically  ||| S:958 E:971 ||| RB
to  ||| S:971 E:974 ||| TO
cells  ||| S:974 E:980 ||| NNS
expressing  ||| S:980 E:991 ||| VBG
target  ||| S:991 E:998 ||| NN
molecules  ||| S:998 E:1008 ||| NNS
and  ||| S:1008 E:1012 ||| CC
accumulated  ||| S:1012 E:1024 ||| VBN
in  ||| S:1024 E:1027 ||| IN
the  ||| S:1027 E:1031 ||| DT
lungs  ||| S:1031 E:1037 ||| NNS
after  ||| S:1037 E:1043 ||| IN
intravenous  ||| S:1043 E:1055 ||| JJ
injection ||| S:1055 E:1064 ||| NN
,  ||| S:1064 E:1066 ||| ,
with  ||| S:1066 E:1071 ||| IN
pulmonary  ||| S:1071 E:1081 ||| NNS
targeting  ||| S:1081 E:1091 ||| VBG
an  ||| S:1091 E:1094 ||| DT
order  ||| S:1094 E:1100 ||| NN
of  ||| S:1100 E:1103 ||| IN
magnitude  ||| S:1103 E:1113 ||| NN
higher  ||| S:1113 E:1120 ||| JJR
than  ||| S:1120 E:1125 ||| IN
free  ||| S:1125 E:1130 ||| JJ
Ab ||| S:1130 E:1132 ||| NNP
.  ||| S:1132 E:1134 ||| .
Most  ||| S:1134 E:1139 ||| RBS
intriguing ||| S:1139 E:1149 ||| JJ
,  ||| S:1149 E:1151 ||| ,
the  ||| S:1151 E:1155 ||| DT
targeting  ||| S:1155 E:1165 ||| VBG
of  ||| S:1165 E:1168 ||| IN
Ab ||| S:1168 E:1170 ||| NNP
/ ||| S:1170 E:1171 ||| NNP
FNPs  ||| S:1171 E:1176 ||| NNP
to  ||| S:1176 E:1179 ||| TO
ICAM-1 ||| S:1179 E:1185 ||| CD
,  ||| S:1185 E:1187 ||| ,
but  ||| S:1187 E:1191 ||| CC
not  ||| S:1191 E:1195 ||| RB
PECAM-1 ||| S:1195 E:1202 ||| CD
,  ||| S:1202 E:1204 ||| ,
surpassed  ||| S:1204 E:1214 ||| VBN
that  ||| S:1214 E:1219 ||| IN
of  ||| S:1219 E:1222 ||| IN
larger  ||| S:1222 E:1229 ||| JJR
Ab ||| S:1229 E:1231 ||| NNP
/ ||| S:1231 E:1232 ||| NNP
carriers  ||| S:1232 E:1241 ||| NNS
targeted  ||| S:1241 E:1250 ||| VBN
by  ||| S:1250 E:1253 ||| IN
the  ||| S:1253 E:1257 ||| DT
same  ||| S:1257 E:1262 ||| JJ
ligand ||| S:1262 E:1268 ||| NN
.  ||| S:1268 E:1270 ||| .
These  ||| S:1270 E:1276 ||| DT
results  ||| S:1276 E:1284 ||| NNS
indicate  ||| S:1284 E:1293 ||| VBP
that  ||| S:1293 E:1298 ||| IN
( ||| S:1298 E:1299 ||| -LRB-
i ||| S:1299 E:1300 ||| FW
)  ||| S:1300 E:1302 ||| -RRB-
FNPs  ||| S:1302 E:1307 ||| NNP
may  ||| S:1307 E:1311 ||| MD
provide  ||| S:1311 E:1319 ||| VB
a  ||| S:1319 E:1321 ||| DT
platform  ||| S:1321 E:1330 ||| NN
for  ||| S:1330 E:1334 ||| IN
targeting  ||| S:1334 E:1344 ||| VBG
endothelial  ||| S:1344 E:1356 ||| JJ
adhesion  ||| S:1356 E:1365 ||| JJ
molecules  ||| S:1365 E:1375 ||| NNS
with  ||| S:1375 E:1380 ||| IN
carriers  ||| S:1380 E:1389 ||| NNS
in  ||| S:1389 E:1392 ||| IN
the  ||| S:1392 E:1396 ||| DT
20  ||| S:1396 E:1399 ||| CD
nm  ||| S:1399 E:1402 ||| JJ
size  ||| S:1402 E:1407 ||| NN
range ||| S:1407 E:1412 ||| NN
,  ||| S:1412 E:1414 ||| ,
which  ||| S:1414 E:1420 ||| WDT
has  ||| S:1420 E:1424 ||| VBZ
not  ||| S:1424 E:1428 ||| RB
been  ||| S:1428 E:1433 ||| VBN
previously  ||| S:1433 E:1444 ||| RB
reported ||| S:1444 E:1452 ||| VBD
;  ||| S:1452 E:1454 ||| :
and  ||| S:1454 E:1458 ||| CC
( ||| S:1458 E:1459 ||| -LRB-
ii ||| S:1459 E:1461 ||| LS
)  ||| S:1461 E:1463 ||| -RRB-
ICAM-1  ||| S:1463 E:1470 ||| NNP
and  ||| S:1470 E:1474 ||| CC
PECAM-1  ||| S:1474 E:1482 ||| NNP
( ||| S:1482 E:1483 ||| -LRB-
known  ||| S:1483 E:1489 ||| VBN
to  ||| S:1489 E:1492 ||| TO
localize  ||| S:1492 E:1501 ||| VB
in  ||| S:1501 E:1504 ||| IN
different  ||| S:1504 E:1514 ||| JJ
domains  ||| S:1514 E:1522 ||| NN
of  ||| S:1522 E:1525 ||| IN
endothelial  ||| S:1525 E:1537 ||| JJ
plasmalemma ||| S:1537 E:1548 ||| NN
)  ||| S:1548 E:1550 ||| -RRB-
differ  ||| S:1550 E:1557 ||| VBP
in  ||| S:1557 E:1560 ||| IN
their  ||| S:1560 E:1566 ||| PRP$
accessibility  ||| S:1566 E:1580 ||| NN
to  ||| S:1580 E:1583 ||| TO
circulating  ||| S:1583 E:1595 ||| VBG
objects  ||| S:1595 E:1603 ||| NNS
of  ||| S:1603 E:1606 ||| IN
this  ||| S:1606 E:1611 ||| DT
size ||| S:1611 E:1615 ||| NN
,  ||| S:1615 E:1617 ||| ,
common  ||| S:1617 E:1624 ||| JJ
for  ||| S:1624 E:1628 ||| IN
blood  ||| S:1628 E:1634 ||| NN
components  ||| S:1634 E:1645 ||| NNS
and  ||| S:1645 E:1649 ||| CC
nanocarriers ||| S:1649 E:1661 ||| NN
.  ||| S:1661 E:1663 ||| .
